Title : Combined effects of PLK1 and RAS in hepatocellular carcinoma reveal rigosertib as promising novel therapeutic "dual-hit" option.

Pub. Date : 2018 Jan 9

PMID : 29423069






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Inhibition of RAS-RAF-ERK-signaling is a major mechanism mediated by the multi-kinase inhibitors sorafenib and regorafenib, the only effective therapeutic approaches for advanced hepatocellular carcinoma (HCC). Sorafenib mitogen-activated protein kinase 1 Homo sapiens